• Sagimet posted a net loss of USD 14 million for Q2 2026, widening from USD 10.39 million a year earlier.
• Research and development expense climbed to USD 11.54 million, general and administrative expense eased to USD 4.28 million.
• Cash, cash equivalents and marketable securities rose to USD 257.56 million as of June 30, 2026, following a USD 175 million April equity financing.
• Denifanstat Phase 3 trial in moderate to severe acne remains on track to start in the second half of 2026.
• CEO David Happel said the company is positioned to fund operations through 2028, including the Phase 3 readout and an NDA submission.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110730PRIMZONEFULLFEED9807099) on August 11, 2026, and is solely responsible for the information contained therein.